- Article metrics
- Last updated: Sat, 20 Apr 2024 6:26:05 Z
2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
Access & Citations
-
- 2377
- Article Accesses
-
- 0
- Web of Science
-
- 5
- CrossRef
Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.